Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis.
Cathrine Dawn Büttner ElgaardLars IversenKasper Fjellhaugen HjulerPublished in: The Journal of dermatological treatment (2022)
Interleukin-23 inhibitors appear to have high and similar drug survival and effectiveness in patients with difficult-to-treat psoriasis and PsA.